Pricing & Access· July 27, 2026 · 18 min read
Multiple Sclerosis Disease-Modifying Therapy Access Landscape (2026)
By Ran Chen#Multiple Sclerosis#Biosimilars#Patent Cliff
Topic
Patent Cliff
Loss of exclusivity, composition-of-matter patent expirations, generic and biosimilar entry timing, and revenue-cliff analysis.